טוען...
Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy
Targeting the amyloid‐β (Aβ) peptide cascade has been at the heart of therapeutic developments in Alzheimer's disease (AD) research for more than 25 years, yet no successful drugs have reached the marketplace based on this hypothesis. Nevertheless, the genetic and other evidence remains strong,...
שמור ב:
| הוצא לאור ב: | Br J Pharmacol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6715594/ https://ncbi.nlm.nih.gov/pubmed/30710367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14593 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|